Related Experiment Video
Updated: Nov 26, 2025
Author Spotlight: Enhancing Coronary Artery Revascularization
Published on: September 15, 2023
MiR-223 levels predicting perioperative bleeding in off-pump coronary artery bypass grafting
Zi Wang1, Limin Xia2, Qing Xu1
1Department of Clinical Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
Insights
Platelet microRNA-223 (miR-223) predicts bleeding risk in off-pump coronary artery bypass grafting (OPCABG) surgery. Ticagrelor therapy increases miR-223 levels more than clopidogrel, potentially explaining differing bleeding outcomes.
Area of Science:
- Cardiovascular Surgery
- Molecular Biology
- Pharmacology
Background:
- Platelet-related microRNAs (miRNAs) may predict bleeding in off-pump coronary artery bypass grafting (OPCABG).
- Dual antiplatelet therapy (DAPT) influences miRNA levels, potentially impacting bleeding risk.
Purpose of the Study:
- Investigate the predictive value of platelet-related miRNAs for bleeding during and after OPCABG.
- Assess the influence of DAPT on miRNA levels and their association with bleeding.
Main Methods:
- Prospective study of 59 patients undergoing OPCABG.
- Measured plasma miR-126 and miR-223 levels and platelet aggregation via thromboelastography during DAPT.
- Compared miRNA levels between ticagrelor and clopidogrel groups; used logistic regression to identify bleeding predictors.
Main Results:
- Higher circulating miR-223 levels and lower BMI independently predicted severe perioperative bleeding in OPCABG.
- Ticagrelor treatment significantly increased circulating miR-223 levels compared to clopidogrel.
Conclusions:
- Plasma miR-223 levels predict bleeding risk in OPCABG.
- Elevated miR-223 with ticagrelor versus clopidogrel may explain differential bleeding outcomes.
- MiR-223 shows potential as a biomarker for bleeding in cardiac surgery.
Background:
To investigate the predictive value of platelet-related microRNAs (miRNAs) for bleeding during and after off-pump coronary artery bypass grafting (OPCABG) and the influence of dual antiplatelet therapy (DAPT) on miRNAs.
Methods:
This prospective study included 59 patients scheduled for OPCABG. The plasma miR-126 and miR-223 levels were measured and platelet aggregation was determined by thromboelastography during DAPT. The plasma miRNA levels were compared between patients treated with ticagrelor or clopidogrel. Multivariable logistic regression analysis was performed to determine the independent risk factors for bleeding during and after surgery. Active bleeding was defined as a blood loss >1.5 mL/kg/h for 6 consecutive hours within the first 24 hours or in case of reoperation during the first 12 postoperative hours. Severe perioperative bleeding was defined using the universal definition of perioperative bleeding in adult cardiac surgery.
Results:
Higher circulating miR-223 levels [odds ratio (OR) =1.348, 95% confidence interval (CI): 1.001-1.814, P=0.047] and lower body mass index (OR =0.648, 95% CI: 0.428-0.980, P=0.040) were independent predictors for severe perioperative bleeding in OPCABG. Ticagrelor treatment led to significant increases in circulating miR-223 levels compared with clopidogrel treatment.
Conclusions:
The plasma miR-223 levels served as a predictor for bleeding during and after OPCABG. Circulating miR-223 levels were significantly elevated with ticagrelor treatment compared with clopidogrel treatment. MiR-223 may be a novel biomarker for bleeding in cardiac surgery and can help explain the different efficacies of ticagrelor and clopidogrel.
More Related Videos
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020